Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease.

Introduction: Randomized clinical trials should be complemented with data from real-world studies. We report our long-term experience with safinamide in a movement disorders unit.

Methods: This retrospective study included patients with Parkinson's disease (PD) treated with safinamide in our unit from February 2016 to May 2022 under routine clinical practice.

Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.

Objectives: To evaluate whether the prescription of monoamine oxidase B inhibitors (MAOB-I), rasagiline and safinamide, contributes to the reduction of levodopa and/or dopamine agonists (DA) dose in order to minimize adverse effects.

Materials And Methods: A total of 724 patients with Parkinson's disease (PD) have been prospectively included in our database since the year 2000, representing a total of 5124 visits. For each patient and visit, antiparkinsonian treatment was recorded.